No abstract

In our study, baseline risk factors and statin use, but not the type of closure, affect perioperative and long-term outcomes after CEA.

AAV conduits may not offer a significant patency advantage in midterm follow-up over prosthetic bypasses.

No abstract

Restenosis or contralateral disease progression after CEA, to a level that might warrant consideration for treatment, is very low. The potentially associated stroke rates are also very low and not clearly related to disease progression. With the exception of the postoperative duplex, surveillance within short intervals of <1 or 2 years cannot be justified.